Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer.
about
Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectivesCancer drug resistance: redox resetting renders a wayIrinotecan, a key chemotherapeutic drug for metastatic colorectal cancerCan knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?Systemic therapies for pancreatic cancer--the role of pharmacogeneticsGermline pharmacogenomics in oncology: decoding the patient for targeting therapyIrinotecan pharmacogenomicsDevelopment and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the simultaneous determination of irinotecan and its main metabolites in human plasma and its application in a clinical pharmacokinetic studyUGT genotyping in belinostat dosingPolymorphisms of uridine glucuronosyltransferase gene and irinotecan toxicity: low dose does not protect from toxicity.Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era.Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients.A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancerAn internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patientsPharmacogene regulatory elements: from discovery to applicationsClinical Implication of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Combined with FOLFIRI in the First-line SettingUncovering drug-responsive regulatory elements.Cancer stem cells and chemoresistance: The smartest survives the raidPharmacogenetics-Guided Phase I Study of Capecitabine on an Intermittent Schedule in Patients with Advanced or Metastatic Solid TumoursPhase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen.UGT1A1 polymorphisms in cancer: impact on irinotecan treatment.Genotypes Affecting the Pharmacokinetics of Anticancer Drugs.An overview of the recent progress in irinotecan pharmacogenetics.Targeted therapy in GIST: in silico modeling for prediction of resistance.Improving oncology outcomes through targeted therapeutics will require electronic delivery systems.Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs.The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens.miRNA pharmacogenomics: the new frontier for personalized medicine in cancer?Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity.Personalizing colon cancer therapeutics: targeting old and new mechanisms of action.Application of genotype-guided cancer therapy in solid tumors.The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis.UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice.Personalizing chemotherapy dosing using pharmacological methods.Nuclear receptors and drug metabolism for the personalization of cancer therapy.North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma.Regulation of carboxylesterase-2 expression by p53 family proteins and enhanced anti-cancer activities among 5-fluorouracil, irinotecan and doxazolidine prodrug.
P2860
Q26741009-FB795202-C126-46D7-B207-3546330996D5Q26750753-B9201C3F-C18D-4A50-9523-4E114E5E2592Q26775949-26F17ADB-0958-4A34-B1F9-0BF0AA1AF542Q26859144-DF62950B-36D6-4B7F-8B03-14ABE4DC3C5BQ27021716-0879A85B-447D-4675-A033-3E9709A941E8Q27022557-2DD99C44-FA74-4B35-A0F2-0A9159B86BEFQ28287024-16960B82-6718-4150-89C7-547D4C80CC86Q28543429-A1F51270-048C-472E-9402-88807D0987B1Q33429235-C512B84A-7A77-4AF9-BFF4-83AEB70CBA30Q33604248-705C1896-EAF9-4A51-81A3-D6297C960B00Q33927990-C500E242-E2C4-4C8F-B67B-639750951095Q34026161-5ABA1D4E-B9F9-48DA-83F5-CDF819427360Q35008045-F6A7926F-AD9A-44BC-BE64-8976611900ACQ35050772-E0165353-3849-4EDF-A0D4-DF2550A26F8DQ35108413-D142DC39-0744-475C-86B6-58C6B0DE28F8Q35603648-1C62E4FF-E360-4225-81FC-96D2469F8315Q36424755-09A3534F-DD84-4F05-A98A-92C52195EE05Q36427498-404FF10E-054A-4E80-8EBE-743F7BB8992EQ36473365-DE560A16-14AF-4B36-B35F-53733032C699Q36730432-24217016-ED06-42AB-A122-11AA812D349AQ37000818-DEEEB540-6573-4832-B87C-2ACDA645E654Q37339628-598F2C3B-F5D7-49F3-A44A-F9F7978995FDQ37383249-2878122A-EAC6-4AFB-98B0-D45E731A398EQ37682812-C2742D4E-6732-47AB-B595-AE9A328C30F1Q37685527-48340745-DF21-4F5B-BB3B-9B47B438A22DQ37710511-70FE3C94-762B-4EAE-987C-43C71426551CQ37848666-EC7D1479-CC68-41A5-A64C-C3886D5A7110Q37875079-59AD5489-01A6-4695-9DB0-9D3DC60CDA35Q37876401-E1435F31-28C8-4CA4-B87F-62DB3BA0B247Q38005612-5FAD88D9-B28A-4D85-99C2-865DCFB3F107Q38059508-E60B845A-7B9A-4E10-8135-EF7A591F9D0AQ38107101-B1F5FED9-CB15-4DE6-8184-1A5CEEE20C73Q38166233-8DD0FE83-5CE3-4EFC-AC46-A7537E609836Q38170457-09F4ECE6-5B41-42C6-A5AB-DD2E77E47D70Q38202816-4E4953A1-FF50-4321-8844-514301087919Q38393997-0D91910E-F0BD-46E0-8287-52C4964800BEQ38571728-98A7EBED-21C2-4387-8149-15C8E63FF1BDQ38704025-4F90833A-43D4-40B5-BD55-C650C5247987Q38792393-A398576C-F25C-4054-9D26-3044E53E824EQ39200965-30564704-7FBC-4F62-9C42-4E5FB3F00385
P2860
Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Genotype-driven phase I study ...... metastatic colorectal cancer.
@en
type
label
Genotype-driven phase I study ...... metastatic colorectal cancer.
@en
prefLabel
Genotype-driven phase I study ...... metastatic colorectal cancer.
@en
P2093
P2860
P50
P356
P1476
Genotype-driven phase I study ...... metastatic colorectal cancer.
@en
P2093
Enrico Mini
Erika Cecchin
Federico Innocenti
Giampiero Gasparini
Giuseppe Azzarello
Mario D'Andrea
Sergio Pessa
Stefania Nobili
P2860
P304
P356
10.1200/JCO.2009.23.6125
P407
P577
2009-12-28T00:00:00Z